Rapport Therapeutics, Inc. Oci Equity Method Investment After Tax Parent
Rapport Therapeutics, Inc. (RAPP) reported Oci Equity Method Investment After Tax Parent of -$765.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:OciEquityMethodInvestmentAfterTaxParent · last filed 2026-08-05
- Rapport Therapeutics, Inc. oci equity method investment after tax parent for the quarter ending 2026-06-30 was -$765.00K, a 4126.32% decline year-over-year.
- Rapport Therapeutics, Inc. oci equity method investment after tax parent for the quarter ending 2026-03-31 was -$1.05M, a 346.14% decline year-over-year.
- Rapport Therapeutics, Inc. oci equity method investment after tax parent for the quarter ending 2025-12-31 was $401.00K.
- Rapport Therapeutics, Inc. oci equity method investment after tax parent for the quarter ending 2025-09-30 was $221.00K, a 62.09% decline year-over-year.
- Rapport Therapeutics, Inc. oci equity method investment after tax parent for fiscal 2025 was $1.07M.
- Rapport Therapeutics, Inc. oci equity method investment after tax parent for fiscal 2024 was -$526.00K, a 13250.00% decline from fiscal 2023.
- Rapport Therapeutics, Inc. oci equity method investment after tax parent for fiscal 2023 was $4.00K.
| Period end | Oci Equity Method Investment After Tax Parent 3 month | Oci Equity Method Investment After Tax Parent 6 month | Oci Equity Method Investment After Tax Parent 9 month | Oci Equity Method Investment After Tax Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$765.00K 10-Q · filed 2026-08-05 | -$1.82M 10-Q · filed 2026-08-05 | -$1.42M derived: sum of 3 quarters · filed 2026-08-05 | -$1.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.05M 10-Q · filed 2026-08-05 | -$650.00K derived: sum of 2 quarters · filed 2026-08-05 | -$429.00K derived: sum of 3 quarters · filed 2026-08-05 | -$410.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $622.00K derived: sum of 2 quarters · filed 2026-03-10 | $641.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.07M 10-K · filed 2026-03-10 |
| 2025-09-30 | $221.00K 10-Q · filed 2025-11-06 | $240.00K derived: sum of 2 quarters · filed 2026-08-05 | $667.00K 10-Q · filed 2025-11-06 | -$255.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $19.00K 10-Q · filed 2026-08-05 | $446.00K 10-Q · filed 2026-08-05 | -$476.00K derived: sum of 3 quarters · filed 2026-08-05 | $107.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $427.00K 10-Q · filed 2026-08-05 | -$495.00K derived: sum of 2 quarters · filed 2026-08-05 | $88.00K derived: sum of 3 quarters · filed 2026-08-05 | $65.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2024-12-31 | -$922.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$339.00K derived: sum of 2 quarters · filed 2026-03-10 | -$362.00K derived: sum of 3 quarters · filed 2026-03-10 | -$526.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $583.00K 10-Q · filed 2025-11-06 | $560.00K derived: sum of 2 quarters · filed 2025-11-06 | $396.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$23.00K 10-Q · filed 2025-11-06 | -$187.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$164.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $4.00K 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |